Close Menu

NEW YORK – Non-invasive algorithmic diagnostics company Fibronostics announced Monday it has raised $8 million in a Series A financing round.

The round was led by Singapore-based private investment firm AT Capital and, a deep-tech venture capital fund. Fibronostics said it has plans to move into new markets and grow its product line and will use the funding to accelerate US commercialization of its Liverfast test, as well as to expand its software platform with new products targeting other diseases, including kidney and lung diseases and COVID-19.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.